LONE

What is the price per share and how does it compare to the current market price?

Created August 08, 2025 at 05:29 PM

Answer

Based on the excerpt you provided, the press‑release only tells us that Longeveron (ticker LONE) has announced the pricing of a public offering that includes common stock and warrants. However, the specific offering price per share is not included in the brief summary you shared, nor is the current market price of LONE’s shares mentioned.

Information Requested	Available in the provided news?
Offering price per share	No – the exact dollar amount per share (or per warrant) is not listed in the summary.
Current market price of LONE	No – the summary does not give LONE’s last traded price or any reference to its market level.

What to Do Next

Locate the Full Press Release
- The full announcement (usually posted on Longeveron’s investor‑relations site or on the GlobeNewswire distribution) will contain a table or paragraph specifying the exact price at which the new shares and warrants are being sold (e.g., “$10.00 per share and $0.50 per warrant”).
Check the Current Market Price
- Use a real‑time market data source (e.g., Bloomberg, Reuters, Yahoo! Finance, or your brokerage platform) to see LONE’s latest trading price.
- Compare the offering price to the market price:
  - If the offering price is **below the market price**, the new issuance is “discounted,” which could be attractive to investors but may be dilutive to existing shareholders.
  - If the offering price is **above the market price**, the company is raising capital at a premium, which is generally less dilutive but may signal confidence in future valuation.
Interpret the Relative Pricing
- Discount: A discount (e.g., offering at $9.00 when the market trades at $10.00) often reflects the need to attract investors quickly or to compensate for the risk of a secondary offering.
- Premium: A premium (e.g., offering at $12.00 when the market trades at $10.00) can indicate that the company believes the new securities carry additional value—perhaps due to attached warrants, conversion features, or strategic rationale disclosed in the full filing.

Sample Framework (if the missing numbers were known)

Metric	Hypothetical Example	Interpretation
Offering price per share	$10.00	–
Current market price	$11.50	The offering is at a ~13% discount to the market, which could be appealing to new investors but will dilute existing shareholders.
Warrant price	$0.50 per warrant (exercise price $5.00)	Provides upside if LONE’s stock rises above $5.00, adding potential value to the overall transaction.

Bottom Line

From the information you supplied: The exact price per share of the public offering and the current market price of LONE are not disclosed.
Action: Retrieve the complete GlobeNewswire release (or the SEC filing accompanying the offering) to obtain the precise pricing details, then look up LONE’s latest trading price on a market data platform to complete the comparison.

If you can share the full press‑release text or the specific pricing figures, I can immediately calculate the percentage difference and discuss the likely impact on existing shareholders and potential investors.

Other Questions About This News

What are the risks of dilution versus the potential upside from the use of proceeds? How will the proceeds be allocated (e.g., R&D, debt repayment, working capital) and what impact will that have on the company’s growth trajectory? What is the expected timeline for closing the offering and any lock‑up periods for insiders? How might this offering impact the company’s ability to fund upcoming clinical or product milestones? What are the potential regulatory or compliance hurdles associated with this public offering? How does this offering size compare to recent offerings by peer biotech/health‑tech companies? How will the $17.5 million offering affect LONE’s share price in the short term? How does the pricing of the offering compare to LONE’s historical valuation multiples? What is the expected dilution percentage from the combined stock and warrant issuance? What is the market’s perception of this capital raise – does it signal confidence or a need for cash? What are the potential impacts on liquidity and trading volume for LONE after the offering? What are the terms of the warrants (exercise price, expiry, conversion ratio) and how might they dilute existing shareholders? How will the offering affect LONE’s balance sheet and cash runway? Are there any covenants or restrictions attached to the securities that could affect future financing?